Literature DB >> 21103811

Cutaneous adverse drug reactions in hospitalised patients.

H Y Lee1, L K Tay, T Thirumoorthy, S M Pang.   

Abstract

INTRODUCTION: Serious adverse drug reactions are common in hospitalised patients. There have been few studies examining the clinical presentation, implicated drugs and outcomes in Singapore.
METHODS: The clinical and laboratory data of all inpatient dermatology consultations with a diagnosis of cutaneous adverse drug reaction were retrospectively analysed over a one-year period.
RESULTS: A total of 97 patients were diagnosed with cutaneous adverse drug reactions. Eight different clinical reaction patterns were noted, namely drug exanthems (46.4 percent), drug rash with eosinophilia and systemic symptoms (18.6 percent), Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum (14.4 percent), urticaria/angioedema (11.3 percent), acute generalised exanthematous pustulosis (3.1 percent), fixed drug eruptions (3.1 percent), generalised exfoliative dermatitis (2.1 percent) and drug-induced vasculitis (1.0 percent). The putative medications included antibiotics (50.5 percent), anticonvulsants (11.3 percent), allopurinol (8.2 percent), chemotherapeutic agents (7.2 percent), nonsteroidal anti-inflammatory agents (7.2 percent), intravenous contrasts (3.2 percent), complementary medications (2.1 percent) and various other medications (10.3 percent). 30 patients were admitted primarily for their adverse drug reaction, with an average length of hospital stay of nine days, while the remaining 67 patients developed these reactions as a complication of their inpatient stay. A total of five deaths were recorded.
CONCLUSION: The presentation of cutaneous adverse drug reactions in hospitalised patients is diverse, ranging from self-limiting and benign reaction patterns to those that are life-threatening. Early recognition, accurate diagnosis, withdrawal of putative medications and specific treatments when indicated may improve outcome.

Entities:  

Mesh:

Year:  2010        PMID: 21103811

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  7 in total

1.  Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis.

Authors:  Qiancheng Deng; Xia Fang; Qinghai Zeng; Jianyun Lu; Chen Jing; Jinhua Huang
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance.

Authors:  Francesca Renda; Giovanni Landoni; Renato Bertini Malgarini; Alessandro Assisi; Maria Luisa Azzolini; Marta Mucchetti; Giuseppe Pimpinella; Luca Pani
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.228

3.  Cutaneous adverse drug reactions in Indian population: A systematic review.

Authors:  Tejas K Patel; Sejal H Thakkar; Dc Sharma
Journal:  Indian Dermatol Online J       Date:  2014-12

4.  Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients.

Authors:  Fatemeh Mokhtari; Zahra Nikyar; Bahareh Abtahi Naeini; Alireza Asemi Esfahani; Siamak Rahmani
Journal:  J Res Med Sci       Date:  2014-08       Impact factor: 1.852

5.  Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore.

Authors:  Si Xian Wong; Mun Yee Tham; Chee Leok Goh; Han Hui Cheong; Sui Yung Chan
Journal:  Pharmacol Res Perspect       Date:  2019-03-13

6.  The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study.

Authors:  Sujaya Manvi; Vikram K Mahajan; Karaninder S Mehta; Pushpinder S Chauhan; Sanket Vashist; Ravinder Singh; Prabal Kumar
Journal:  Indian Dermatol Online J       Date:  2022-01-24

7.  Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China.

Authors:  Shi Qing-ping; Jiang Xiao-dong; Ding Feng; Liu Yan; Yu Mei-ling; Zhu Jin-xiu; Zhang Shu-qiang
Journal:  BMC Health Serv Res       Date:  2014-02-17       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.